Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cellect Biotechnology (APOP) stocks in Canada

Learn how to easily invest in Cellect Biotechnology stocks.

Cellect Biotechnology is a biotechnology business based in the US. Cellect Biotechnology stocks (APOP.US) are listed on the NASDAQ and all prices are listed in US Dollars. Cellect Biotechnology employs 12 staff and has a market cap (total outstanding stock value) of $12.9 million.

How to buy shares in Cellect Biotechnology

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – APOP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cellect Biotechnology stock price (NASDAQ:APOP)

Use our graph to track the performance of APOP stocks over time.

Cellect Biotechnology shares at a glance

Information last updated 2021-12-26.
52-week range$8.40 - $35.52
50-day moving average $17.38
200-day moving average $7.39
Wall St. target price$12.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.85

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Cellect Biotechnology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Cellect Biotechnology price performance over time

Historical closes compared with the close of $N/A from 2021-11-26

1 week (2022-01-15) N/A
1 month (2021-12-22) N/A
3 months (2021-10-26) -100.00%
6 months (2021-07-26) -100.00%
1 year (2021-01-26) -100.00%
2 years (2020-01-24) -100.00%
3 years (2019-01-25) -100.00%
5 years (2017-01-26) -100.00%

Cellect Biotechnology financials

Gross profit TTM $0
Return on assets TTM -47.79%
Return on equity TTM -120.42%
Profit margin 0%
Book value $0.69
Market capitalisation $12.9 million

TTM: trailing 12 months

Cellect Biotechnology share dividends

We're not expecting Cellect Biotechnology to pay a dividend over the next 12 months.

Have Cellect Biotechnology's shares ever split?

Cellect Biotechnology's shares were split on a 1:4 basis on 23 September 2021. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cellect Biotechnology shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Cellect Biotechnology shares which in turn could have impacted Cellect Biotechnology's share price.

Cellect Biotechnology share price volatility

Over the last 12 months, Cellect Biotechnology's shares have ranged in value from as little as $8.4 up to $35.52. A popular way to gauge a stock's volatility is its "beta".

APOP.US volatility(beta: 1.88)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellect Biotechnology's is 1.8767. This would suggest that Cellect Biotechnology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cellect Biotechnology overview

As of October 28, 2021, Cellect Biotechnology Ltd. was acquired by Quoin Pharmaceuticals, Inc. , in a reverse merger transaction. Cellect Biotechnology Ltd. , a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. The company develops ApoTainer, a kit for hematopoietic stem cell transplantation procedures. It has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; Cell2in Inc.

Cellect Biotechnology in the news

There are no recent company news

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site